ACRX News and Press, AcelRx Pharmaceuticals Inc. From 08/10/23

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits...

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 PR Newswire HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the developme...

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire Transformative capital raise, led by new investors including Nantahala Capital Management The private placement provides access to up ...

2023-07-18 08:39:23 ET Specialty pharmaceutical company AcelRx Pharmaceuticals ( NASDAQ: ACRX ) said on Tuesday that it has launched an ~$10M private placement of shares. The company has entered into a definitive agreement for the purchase and sale of an aggregate of 5.3M shar...

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules PR Newswire Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross p...

2023-05-10 20:28:06 ET AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vincent Angotti – Chief Executive Officer Pam Palmer – Co-Found...

2023-05-10 16:12:29 ET AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q1 GAAP EPS of -$0.75 beats by $0.04 . The cash and cash equivalents balance was $13.4 million as of March 31, 2023. Combined R&D and SG&A expenses for the first quarter of 2023 t...

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 20...

2023-05-09 17:35:57 ET AcelRx Pharmaceuticals ( NASDAQ: ACRX ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue Estimate is $1.65M (+275.0% Y/Y). Over the last 3 mont...

AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 PR Newswire HAYWARD, Calif. , April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development ...